The global cardiometabolic disease market was valued around USD 120.4 Bn in 2021 and is poised to grow at a significant CAGR of 3.8% over 2022-2028. Some of the key factors influencing the market growth include growing demand for a healthy lifestyle as it a crucial for maintenance. Due to rapidly changing lifestyle, food habits and genetic predisposition, rising in the incidence of various diseases such as diabetes, high cholesterol, cardiovascular disease, hypertension and others. Additionally, increasing awareness and government initiatives on public healthcare will fuel the market growth. Huge demand for plants based nutritional products and treatment requires a combination of nourishing, behavioral, and drug treatments, wherein drugs act as an assistant to behavioral therapies. Additionally, increase in acceptance of dietary food supplements and technological advancement in biotechnology for launching new products boosting the market growth. However, lack of awareness among the aged population and lack of standard norms and regulations regarding the medical facilities are some of the factor hinder the market growth. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global cardiometabolic disease market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global cardiometabolic disease market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).
In Oct 2021, Boehringer Ingelheim and Eli Lilly and Company launched CRMSynced, a gamified teaching program that encourages healthcare providers to prioritize a holistic approach to care for cardio-renal-metabolic (C-R-M) problems. Recent advancements in C-R-M treatment and standards have shifted the burden of care to all members of the patient care team, including primary care physicians, specialists, and advanced practice clinicians.
In Nov 2021, Novo Nordisk acquired Dicerna Pharmaceuticals including the RNAi research technology platform. Dicerna’s expertise in RNAi and oligonucleotide therapeutics, as well as its highly skilled employees, combined with Novo Nordisk’s industry leadership in developing and commercializing medicines to treat serious chronic diseases, has the potential to significantly accelerate and expand our mission to deliver GalXC RNAi therapies for the benefit of patients and all of our stakeholders.